Clinical Trials Directory

Trials / Completed

CompletedNCT02901275

Enhancing Medication-based Analgesia in Humans

Using Dronabinol to Enhance the Analgesic Effect of Hydromorphone in Humans

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
29 (actual)
Sponsor
Johns Hopkins University · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Accepted

Summary

This is a single-group, within-subject, double-blind, double-dummy, placebo and active-controlled study evaluated whether the FDA-approved cannabinoid dronabinol (Marinol) would enhance analgesia, subjective reports, and cognitive performance when compared to the FDA-approved opioid hydromorphone (Dilaudid).

Detailed description

This was a human laboratory systematic examination of whether adding the FDA-approved cannabinoid dronabinol (Marinol; oral) to the FDA-approved opioid hydromorphone (Dilaudid; oral) would change the experience of hydromorphone as rated by laboratory measures of pain, subjective reports of drug effects, and cognitive performance. Subjects are healthy individuals with no history of drug use disorder. Study subjects and staff were completed blinded to the study drugs and the class of drugs under investigation and were informed that subjects may receive opioids, stimulants, cannabinoids, benzodiazepines, over the counter medications, and/or placebo. All participants completed all sessions. Sessions lasted up to 8-hours and were conducted at least 7 days apart on an outpatient basis. Primary outcomes were collected from participants prior to dosing and at several hour periods post-dosing.

Conditions

Interventions

TypeNameDescription
DRUGWithin-subject test of blinded study medicationsWithin-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.

Timeline

Start date
2016-12-01
Primary completion
2020-03-23
Completion
2020-03-23
First posted
2016-09-15
Last updated
2023-11-07
Results posted
2021-06-07

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02901275. Inclusion in this directory is not an endorsement.